SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: TTPH, Tetraphase Pharmaceuticals

No earlier versions found for this Subject.


Return to TTPH, Tetraphase Pharmaceuticals
 
Tetraphase has hit a snag, failing inferiority testing with an antibiotic at phase III. The company should be considered as having two phase I clinical trial programs, with one of those molecules having passed a single phase III trial. Current plans are to file in Europe for eravacycline, but it's back to phase I for the U.S.

Last share offering, 3/15, was at $35.

Current shares (1/28/16) are going for $5.18.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News